Replies to post #226590 on Biotech Values

[DewDiligence]

AGRX -31%/AH on 3-month PDUFA extension:

https://www.globenewswire.com/news-release/2019/11/14/1947637/0/en/Agile-Therapeutics-Announces-FDA-Extension-of-Twirla-NDA-Review-Period.html

[DewDiligence]

AGRX acquired for $1.52/sh cash—a 336% premium to yesterday’s closing price:

https://www.globenewswire.com/news-release/2024/06/26/2904429/30925/en/Agile-Therapeutics-Inc-Announces-Definitive-Merger-Agreement-with-Insud-Pharma-S-L.html

Despite the large premium to yesterday’s close, this transaction is essentially a takeunder in that AGRX is down >99% from where it traded in 2019.

The buyer is Insud Pharma, which is based in Spain. The nominal deal value is $45M.